Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
BMI of 30 or above, or BMI of 27 or above with an obesity-related health condition Health conditions such as high blood pressure, insulin resistance, sleep apnea, or elevated cholesterol History of unsuccessful attempts with diet, exercise, or commercial weight loss programs Willingness to combine medication with nutrition, movement, and lifestyle changes Not currently pregnant or planning pregnancy in the near term No contraindications to GLP-1 therapy based on health history and provider review Candidacy for compounded semaglutide and compounded tirzepatide is reviewed individually
Be aware that compounded semaglutide may have varying potency compared to standard formulations
In August 2025, the FDA approved using Wegovy semaglutide injections to treat MASH in adults who have moderate-to-advanced liver scarring
Drug-induced hyperkalemia: Old culprits and new offenders
Differential effect of short-term popular diets on TMAO and other cardio-metabolic risk markers
